Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia

Inclusion Criteria:

AML favorable or intermediate ELN risk
Achieved true 1st complete response (CR) (absolute neutrophil count [ANC] and platelet count > 1,000/ul and 100,000/ul respectively) after first cycle of induction therapy, with no minimal residual disease (MRD)
No measurable residual disease (MRD) as assessed by flow cytometry after initial induction therapy
Performance score Eastern Cooperative Oncology Group (ECOG) 0, 1 or 2
Creatinine < 2.0 mg/dl and calculated by Cockcroft-Gault (CG) formula or 24 hour measured creatinine clearance (CRCL) > 50
Not pregnant
Received 1-2 courses of post remission "consolidation" therapy prior to mobilization PBSC
No MRD by flow, cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing prior to collection of autologous PBSC collection
Plan is to collect at least 3 x 10^6 CD34+ PBSC/kg cryopreserved; preference is 4-5 X 10^6 CD34 cells/kg

Exclusion Criteria:

Life expectancy is severely limited by diseases other than AML
Total bilirubin > 2.0 mg/dl or serum glutamic-oxaloacetic transaminase (SGOT)/serum glutamate pyruvate transaminase (SGPT) > 2.5 x upper limit of normal (ULN)
History of Gilbert's disease
Uncontrolled arrhythmias, left ventricular ejection fraction (LVEF) < 50% or corrected diffusion capacity of the lung for carbon monoxide (DLCO) < 50%
Significant active infection that precludes transplant
Hepatitis B or C viremia at time of ASCT
History of central nervous system (CNS) involvement with AML